title: The new age of liver transplantation.
abstract: The advent of cyclosporin A for immunosuppression (IS) in liver transplantation (LTx) in the early 1980s heralded a new age for LTx, resulting in widespread application, rapidly expanding indications, relaxation of restrictions in donor selection and advances in the preservation of liver grafts and management of LTx operations. Liver transplantation, together with the transplantation of other organs (kidney, pancreas, heart, heart-lung, intestine), became possible. In Australia, around 125 LTx (22% in children) are performed each year. Indications are: primary sclerosing cholangitis; primary biliary cirrhosis; auto-immune hepatitis; chronic viral hepatitis; biliary atresia; metabolic disorders; fulminant hepatic failure (FHF); alcoholic cirrhosis; and malignancy (cancer, CA). Since 1965, 810 patients underwent LTx and 70 (9%) re-Tx. Patient survivals at 1, 5 and 9 years post-Tx are 80, 74 and 66%, respectively. Patients with primary diseases that recur in the LTx (hepatitis B and CA) do less well following LTx, with 5-year survival rates of 55 and 40%, respectively). Recent developments include: increasing the availability of donor organs by the use of living donors, 'split' cadaveric donor (CD) grafts, 'marginal' and non-heart-beating CD grafts and xenografts; expanding the indications for LTx; development of effective liver support systems for patients with FHF; the treatment of diabetics with liver failure with islet Tx (at the time of LTx); more effective immunosuppression; and methods to diminish recurrent disease in LTx. Some understanding of the unique 'tolerogenic' capabilities of the liver has come with the recognition of 'two-way microchimerism'. The satisfactory 5-9 year outcomes for patients underline the cost-effectiveness of LTx.
authors.affiliation: Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Royal Alexandra Hospital for Children, University of Sydney, New South Wales, Australia.
authors.forename: A G
authors.initials: AG
authors.lastname: Sheil
mesh_terms: D001315:Australia; D003362:Cost-Benefit Analysis; D006501:Hepatic Encephalopathy / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008107:Liver Diseases / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D019520:Living Donors; D018579:Patient Selection; D012086:Reoperation; D014019:Tissue Donors; D014021:Tissue Preservation / Q000379:methods; D014183:Transplantation, Heterologous; D016896:Treatment Outcome